News

FDA's counsel accused of being too close to drug industry

BMJ 2004; 329 doi: http://dx.doi.org/10.1136/bmj.329.7459.189 (Published 22 July 2004) Cite this as: BMJ 2004;329:189
  1. Jeanne Lenzer
  1. New York

    Daniel Troy, chief counsel to the US Food and Drug Administration, is under fire for inviting drug companies to inform him of lawsuits against them so the FDA could help in their defence. “We can't afford to get involved in every case—we have to pick our shots,” he said, advising them therefore to “make it sound like a Hollywood pitch.”

    Congressman Maurice Hinchey of New York charges Mr Troy with a “pattern of collusion” with drug and medical device manufacturers. Mr Hinchey told the BMJ that the FDA had “corrupted its mission to protect the public health” and that Mr Troy “is aggressively intervening against the public on behalf of drug companies and medical device manufacturers.”

    Mr Troy's supporters insist that it has been necessary for him to involve himself in court cases to protect the interests of the FDA. The agency says that court plaintiffs are intruding more heavily on the FDA's primary jurisdiction than ever before and it wants to …

    View Full Text

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe